Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody.
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The table below is a review of notable updates that occurred in January 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug Pharmacologic Class Proposed Indication Status Cardiovascular Disease Bumetanide nasal spray (RSQ-777; Corstasis Therapeutics) Loop diuretic Treatment of edema associated with congestive heart…
Drug Pharmacologic Class Indication More Information Endocrine Disorders Ozempic (semaglutide) Glucagon-like peptide-1 receptor agonist To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease Gastrohepatic Disorders…
“Until now, we have only had stool-based tests and colonoscopy or sigmoidoscopy. A blood test has the potential for improving colorectal cancer screening rates.”
Encorafenib, a kinase inhibitor, is currently marketed under the brand name Braftovi.
Summary of important additions and changes to the MPR drug database.
50 percent of patients with CIN3 had histopathological complete response; 63 percent had HPV16 clearance
However, overall, the absolute risk for thyroid cancer is low